August 2026 Research Update

In a large international study of people with alternating hemiplegia of childhood (AHC), the most vulnerable period looked like early childhood, when thinking skills and non-attack (non-paroxysmal) disability tended to worsen, while many areas looked more stable after age 5. This helps build a clearer picture that AHC progression is not simply a steady decline every year, but can be more concentrated in the early years. The same study also reported that epilepsy and some ATP1A3 variants tracked with worse disability scores, suggesting that AHC can follow different paths for different people. [1]

Before age 5, the study measured declines in intellectual and adaptive functioning scores, and worsening non-paroxysmal disability, while after age 5 these measures were not clearly tied to age. Motor classification scores for gross and hand function did not show clear age-related change, while a disability score tied to attack-related symptoms showed a trend toward improvement that the authors linked to changes in plegia after age 5. Put simply, this report separated "attack-related" difficulties from "everyday baseline" difficulties and found they did not move in lockstep over time. [1]

The study also identified factors that helped explain who tended to have a harder course. Epilepsy was linked with worse scores for intellectual disability and for gross and hand motor function, and early-life disability scores predicted worse later outcomes. Two well-known variants were linked to different patterns: D801N tracked with worse attack-related disability, while E815K tracked with worse intellectual disability scores. [1]

Mortality was measured during follow-up and included sudden unexpected death in epilepsy (SUDEP) among those with epilepsy. The paper reported 3 deaths during follow-up, and provided rates that quantify risk in this cohort rather than describing it as rare or common without context. This adds to the evidence that epilepsy is not only a symptom in AHC, but also one driver of long-term risk in at least some families. [1]

For patients and caregivers, this month added a clearer timeline: many measured difficulties were most likely to worsen in the first years of life, and then often looked more stable after age 5 in this cohort. This does not predict what will happen for any one child, but it helps explain why two children with AHC can look very different by school age even if they started similarly. The findings may matter now for understanding prognosis and planning support, but they are based on observed patterns rather than a treatment that changes the course. [1]

What remains uncertain is how well these age-related patterns apply to infancy, later adulthood, and people not captured by specialty centers, since follow-up was 1 to 3 years and the age range was limited. Even with that uncertainty, the study helps clarify that epilepsy and specific ATP1A3 variants can be meaningful markers of a tougher course, which may be useful in future research that aims to better predict outcomes or test interventions. [1]

This month included a reminder that ATP1A3-related conditions sit on a spectrum rather than in perfectly separate boxes. In a Brazilian multicenter report of 41 people with ATP1A3 variants, individuals were classified into seven different clinical presentations, yet many features overlapped across the classic syndrome names. The study also reported that age at onset differed by the specific genetic variant, supporting the idea that the exact change in ATP1A3 can shape how and when symptoms appear. [2]

The report included AHC as the most common presentation in this group, but it also included movement disorders, episodic weakness with other neurologic features, and rarer severe early-onset conditions. Brain imaging and electrical tests were sometimes abnormal, including cerebellar atrophy as a common imaging finding among those with abnormal MRIs. The study also noted a single person with a prolonged QTc on ECG, showing that heart rhythm screening can come up in ATP1A3 care discussions even if it is not the main issue for most people. [2]

Information about medication experience in routine care was mixed and incomplete, but it gave a snapshot of what families are trying. Flunarizine was reported with reduced hemiplegic episodes in some people, while levodopa helped only 1 out of 11 who tried it, and topiramate in AHC had mixed responses including one report of worsening. Because these were not controlled comparisons and records were sometimes missing, the results describe what happened in this set of patients rather than proving what works best. [2]

For families, this study mainly adds context: an ATP1A3 result does not automatically point to a single, neatly defined syndrome, and overlap between labels is common. This can help explain why two people with ATP1A3 changes may have different combinations of episodes, movement symptoms, learning challenges, or imaging findings. The medication notes may matter now as a realistic picture of mixed responses reported in routine care, but they do not settle which treatments help most. [2]

What remains uncertain is how generalizable these exact percentages are to other countries or clinics, since this was a chart-based snapshot with some missing data and no standardized treatment testing. Even so, the study strengthens a practical takeaway for research: linking specific variants to age at onset and symptom patterns may be one path toward more personalized prediction in the future. [2]

A laboratory study this month dug into how the Na+/K+-ATPase pump (the protein affected by ATP1A3 changes) moves through working states and how a disease-causing change could alter that behavior. It captured several structural states during pump activity and described differences between the alpha3 and alpha1 isoforms in sodium handling. It also showed that an alpha3 Q140L mutant disrupted a pocket that binds certain membrane fats (phospholipids), and the mutant had reduced stimulation by polyunsaturated phospholipids. [3]

The key message is that ATP1A3-related disease can be influenced not only by the gene change itself but by how the altered pump interacts with its surrounding membrane environment. By mapping where sodium binds and how the pump transitions between steps, the work adds a more concrete picture of what "pump dysfunction" can mean at the molecular level. This kind of evidence is early, but it can guide future experiments that test whether these structural differences relate to cell and brain function. [3]

For patients and caregivers, this is early-stage research that does not translate into a new test or treatment right now. Its value is in making the biology less abstract: it shows specific parts of the pump that can be disturbed by a disease-linked change, and it points to membrane fats as one factor that might affect pump activity in the lab. This may matter later if it helps researchers design targeted therapies or better ways to classify which variants disrupt which step of pump function. [3]

What remains uncertain is how directly these laboratory findings predict symptoms or day-to-day outcomes in AHC, since the work was done on recombinant proteins rather than in patients. Even with that limitation, the study helps clarify a plausible mechanism pathway: certain variants may weaken the pump by altering how it binds and is supported by the cell membrane. [3]